Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression

Prostate

Volumn 54, Issue 1, 2003, Pages 8-16

  Huss, Wendy J ^a,c   Barrios, Roberto J ^a   Foster, Barbara A ^b   Greenberg, Norman M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; FGF 2; FGFR1; FGFR2; Prostate cancer; TRAMP

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; ISOPROTEIN; LIGAND; MESSENGER RNA;

ADENOCARCINOMA; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENETIC CODE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; TRANSGENIC MOUSE; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; LIGANDS; MALE; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0037220643     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10163     Document Type: Article

References (34)

1. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 1992;13:465-475.
2. Thomson AA. Role of androgens and fibroblast growth factors in prostatic development. Reproduction 2001;121:187-195.
3. Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999;274:12827-12834.
4. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-1071.
5. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992;52:571-577.
6. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993;60:1-41.
7. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-15297.
8. Ornitz DM. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 2000;22:108-112.
9. Gimbrone MAJ, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-276.
10. Kandel J, Bossy-Wetzel E, Radvanyl F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66:1095-1104.
11. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
12. Dow JK, deVere White RW. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 2000;55:800-806.
13. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-165.
14. Connolly JM, Rose DP. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 1998;160:932-936.
15. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
16. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996;24:502-504.
17. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;6:1-6.
18. Foster BA, Kaplan PJ, Greenberg NM. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:76-82.
19. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001;61:2736-2743.
20. Kawasaki ES. Amplification of RNA. In: Innis GD, Sninsky JJ, White TJ, editors. PCR Protocols: A Guide to Methods and Application. New York: Academic Press; 1990. p. 21-27.
21. Hebert JM, Basilico C, Goldfarb M, Haub O, Martin GR. Isolation of cDNAs encoding four mouse FGF family members and characterization of their expression patterns during embryogenesis. Dev Biol 1990;138:454-463.
22. Alam KY, Frostholm A, Hackshaw KV, Evans JE, Rotter A, Chiu IM. Characterization of the 1B promoter of fibroblast growth factor 1 and its expression in the adult and developing mouse brain. J Biol Chem 1996;271:30263-30271.
23. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992;12:82-88.
24. Safran A, Avivi A, Orr-Urtereger A, Neufeld G, Lonai P, Givol D, Yarden Y. The murine flg gene encodes a receptor for fibroblast growth factor. Oncogene 1990;5:635-643.
25. Mansukhani A, Dell'Era P, Moscatelli D, Kornbluth S, Hanafusa H, Basilico C. Characterization of the murine BEK fibroblast growth factor (FGF) receptor: Activation by three members of the FGF family and requirement for heparin. Proc Natl Acad Sci USA 1992;89:3305-3309.
26. Mydlo JH, Kral JG, Volpe M, Axotis C, Macchia RJ, Pertschuk LP. An analysis of microvessel density, androgen receptor, p53, and HER-2/neu expression and Gleason Score in prostate cancer. Eur Urol 1998;34:426-432.
27. Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen). Prostate Cancer Prostatic Dis 1997;1:32-38.
28. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-465.
29. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
30. Prats H, Kaghad M, Prats AC, Klagsbrun M, Lelias JM, Liauzun P, Chalon P, Tauber JP, Amalric F, Smith JA, Caput D. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci USA 1989;86:1836-1840.
31. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001;46:163-172.
32. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997;15:3059-3065.
33. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997;57:5369-5378.
34. Estival A, Monzat V, Miquel K, Gaubert F, Hollande E, Korc M, Vaysse N, Clemente F. Differential regulation of fibroblast growth factor (FGF) receptor-1 mRNA and protein by two molecular forms of basic FGF. Modulation of FGFR-1 mRNA stability. J Biol Chem 1996;271:5663-5670.